Among a growing cluster of Pittsburgh biotechs, you'll find BlueSphere Bio, an early-stage company discovering T cell receptors to leverage against tumor-specific antigens in individual cancer patients. Its leader, CEO Keir Loiacono, Esq., works with a sense of urgency inspired by his own cancer journey. The Business of Biotech toured BlueSphere's state-of-the-art facility and sat down with Loiacono to discuss the company's vision for the future of personalized, adoptive cell therapy. Listen now!
In this article, we discuss CDMO assessment and show how to construct an agreement between partners that favors fluid communication and alignment of business objectives — crucial for a fruitful sponsor-CDMO relationship to diminish overall risk for both.
ISR explains how LSL’s CDMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CDMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.
Decentralized clinical trials (DCTs) offer clear benefits to patients and the overall success of the trial, but it can be difficult to know how to address this challenge. This three-stage framework approach will enable you to assess your organization’s current clinical trial innovation maturity and build a plan from there.
This webinar reviews the impact of regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.
It is possible to develop key performance indicators (KPIs) for your medical affairs team through building a framework for understanding success that embraces both quantitative and qualitative metrics.